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Abstract
Background—Dual antiplatelet therapy is recommended after coronary stenting to prevent
thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain.
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Methods—Subjects were enrolled after a drug-eluting coronary stent procedure. After 12 months
of thienopyridine (clopidogrel bisulfate [Plavix] or prasugrel [Effient/Efient]) with aspirin,
subjects were randomized to continued thienopyridine or placebo for another 18 months; all
continued aspirin. The co-primary effectiveness end points were stent thrombosis and major
adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or
stroke) at 12 to 30 months. The primary safety end point was moderate or severe bleeding.
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Results—Subjects (N=9,961) were randomized to continued thienopyridine or placebo.
Continued thienopyridine reduced stent thrombosis (0.4% vs. 1.4%, hazard ratio 0.29, 95%
confidence interval [CI] 0.17-0.48, P<0.001) and major adverse cardiovascular and
cerebrovascular events (4.3% vs. 5.9%, hazard ratio 0.71, 95% CI 0.59-0.85, P<0.001).
Myocardial infarction was reduced (2.1% vs. 4.1%, hazard ratio 0.47, P<0.001). Rates of all-cause
mortality in the continued thienopyridine and placebo groups were 2.0 and 1.5%, respectively
(hazard ratio 1.36, 95% CI 1.00-1.85, P=0.052). Moderate or severe bleeding was increased with
continued thienopyridine (2.5% vs. 1.6%, P=0.001). An elevated hazard for stent thrombosis and
myocardial infarction was observed in both groups during the 3 months following thienopyridine
discontinuation.
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Conclusion—Dual antiplatelet therapy beyond one year after drug-eluting stent placement
significantly reduced the risks of stent thrombosis and major adverse cardiovascular and
cerebrovascular events compared with aspirin alone, but was associated with increased bleeding.

Introduction
Millions of patients worldwide receive coronary stents each year for the treatment of
ischemic heart disease.1,2 Although drug-eluting stents reduce restenosis compared with
bare metal stents, there is concern that drug-eluting stents may be associated with risks of
stent thrombosis occurring beyond one year after treatment.3 Stent thrombosis, while rare, is
frequently associated with myocardial infarction, and may be fatal.3 Furthermore, ischemic
events such as myocardial infarction, stroke, or cardiovascular death, unrelated to the treated
coronary lesion, also occur beyond one year.4,5
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The use of dual antiplatelet therapy combining a P2Y12 receptor inhibitor with aspirin is
critically important to prevent coronary stent thrombosis, and is currently recommended for
6 to 12 months after implantation of a drug-eluting stent.6,7 While some observational
studies suggest that extending dual antiplatelet therapy beyond one year is associated with a
lower risk of myocardial infarction following drug-eluting stent treatment8, several trials
have also demonstrated increased risk of bleeding without lowering myocardial infarction
incidence with longer therapy.9-12 Whether treatment with dual antiplatelet therapy beyond
one year reduces either coronary stent thrombosis or ischemic events remote to the stent has
not been determined by an adequately powered randomized trial.
The Dual Antiplatelet Therapy (DAPT) Study was an international, multicenter, randomized
placebo-controlled trial to determine the benefits and risks of continuing dual antiplatelet
therapy beyond one year after treatment with coronary stents.
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Methods
Study Design
The DAPT Study design has been described previously.13 The trial was designed in
response to a request from the United States Food and Drug Administration (FDA) to
manufacturers of coronary stents, and was conducted under an investigational-device
exemption through a public-private collaboration involving the FDA, eight funding stent and
pharmaceutical manufacturers (see Supplementary Appendix), and Harvard Clinical
N Engl J Med. Author manuscript; available in PMC 2015 June 26.
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Research Institute (HCRI). The stent manufacturers who contributed to the funding of the
trial had contributing roles in trial design and in data collection as detailed in the
Supplementary Appendix. HCRI was responsible for the scientific conduct and independent
analysis of the trial.
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A single uniform randomized trial was designed incorporating five individual component
studies to facilitate enrollment (Supplementary Appendix). Subjects were enrolled into the
trial either by HCRI or from one of four post-marketing surveillance studies designed to
collect similar clinical data in similar patient populations. Each contributing study followed
uniform randomization criteria and follow-up as specified by the overall DAPT Study
protocol. A single clinical events committee blinded to the randomized treatment assignment
adjudicated events, and an unblinded independent central data monitoring committee
oversaw the safety of all subjects. All participating institutions received institutional review
board approval.
The first three authors and the last author, who wrote the manuscript under the coordination
of HCRI, had full access to the data; they vouch for the integrity of the analyses presented
and for the fidelity of this report to the trial protocol, which is available with the full text of
this article at NEJM.org. The manuscript was provided to the funding manufacturers for
review in advance of publication; however, they did not have the right of refusal except with
regard to individual manufacturer confidential information.
Study Population
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Adults who were candidates for dual antiplatelet therapy following treatment with FDAapproved drug-eluting or bare metal stents were enrolled. Detailed inclusion and exclusion
criteria are listed in the Supplementary Appendix. Each subject provided written informed
consent at enrollment.
The primary analytic population and focus of this report is subjects treated with drug-eluting
stents only (results in subjects treated with bare metal stents will be reported in a separate
publication; see Figure 1). Drug-eluting stents included sirolimus-eluting stents (Cypher,
Cordis), zotarolimus-eluting stents (Endeavor, Medtronic), paclitaxel-eluting stents
(TAXUS, Boston Scientific), and everolimus-eluting stents (Xience, Abbott Vascular and
PROMUS, Boston Scientific). It was recommended that all subjects receive either
clopidogrel at a maintenance dose of 75 mg daily or prasugrel at a maintenance dose of 10
mg daily (a dose of 5 mg daily was recommended in subjects weighing less than 60 kg).13
The recommended maintenance aspirin dosage was 75 to 162 mg daily, continued
indefinitely.

Author Manuscript

Study Procedures
Subjects were enrolled within 72 hours of stent placement and were given open-label aspirin
and thienopyridine for 12 months. At 12 months, subjects who were both event-free (from
major adverse cardiovascular and cerebrovascular events, repeat revascularization, or
moderate or severe bleeding) and compliant with thienopyridine (defined as having taken
80% to 120% of the drug without an interruption of longer than 14 days) were eligible for
randomization (see Figure 1).
N Engl J Med. Author manuscript; available in PMC 2015 June 26.
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Eligible subjects continued aspirin and were randomized in a 1:1 ratio to continued
thienopyridine or placebo for an additional 18 months (months 12 to 30 after enrollment). A
computer-generated randomization schedule stratified subjects by stent type (drug-eluting
versus bare metal stent), hospital site, thienopyridine type, and presence or absence of at
least one prospectively-defined clinical or lesion-related risk factor for stent thrombosis (risk
factors listed in Table S1 of the Supplementary Appendix).13 After completing the
randomized treatment period, subjects were followed for a 3-month observational period on
aspirin alone (months 30 to 33 after enrollment) to assess the effect of thienopyridine
discontinuation on end point event rates.
End Points
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The co-primary effectiveness end points were the cumulative incidence of definite or
probable stent thrombosis14 and major adverse cardiovascular and cerebrovascular events
(defined as the composite of death, myocardial infarction or stroke) during the randomized
treatment period (months 12 to 30). The primary safety end point was the incidence of
moderate or severe bleeding during this same period (Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Arteries [GUSTO] classification).15
Bleeding was also evaluated according to the Bleeding Academic Research Consortium
[BARC] definitions.16 End point definitions are provided in the Supplementary Appendix.
After the primary analysis had been completed, a second blinded clinical events committee
was convened to adjudicate non-cardiovascular causes of death.
Statistical Analysis
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The primary efficacy analysis was a superiority analysis performed using the log-rank test,
stratified by geographic region (North America, Europe, or Australia and New Zealand),
thienopyridine type at randomization, and presence or absence of stent thrombosis risk
factors, controlling the two-sided family-wise error rate of 0.05 across the two co-primary
end points using the Benjamini-Hochberg method.17 Using this method, the null hypothesis
of randomized treatment equivalence is rejected if significance is achieved on both end
points at a two-sided alpha = 0.05, or on one end point at a two-sided alpha = 0.025. We
assumed annual placebo event rates of 0.5% for stent thrombosis and 2.9% for major
adverse cardiovascular and cerebrovascular events; hazard ratios of 0.45 for stent
thrombosis and 0.75 for major adverse cardiovascular and cerebrovascular events for
continued thienopyridine vs. placebo; and up to 3% annual loss to follow-up. Given these
assumptions, a sample size of 9,800 randomized subjects receiving drug-eluting stents
yielded at least 85% power. This sample size was reduced from the 12,196 specified in the
original protocol based on changes made in statistical parameters before enrollment was
completed and without inspection of the study data (as described in the Supplementary
Appendix).
The primary safety analysis was a non-inferiority analysis performed using the FarringtonManning risk difference approach18. Assuming an annualized moderate or severe bleeding
rate of 1.9%, and an absolute non-inferiority margin (δ) of 0.8%, at an alpha = 0.025 (1sided) significance, a sample size of 9,960 subjects provided 80% power to detect noninferiority.

N Engl J Med. Author manuscript; available in PMC 2015 June 26.
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For major adverse cardiovascular and cerebrovascular events and stent thrombosis, the
primary analyses were performed on all randomized subjects treated with drug-eluting stents
(the intention-to-treat principle). Kaplan-Meier estimates of the cumulative incidence of
each end point are presented by treatment group, with 2-sided 95% confidence intervals (CI)
of stratified hazard ratios. Subjects not experiencing an end point were censored for the
analysis on that end point at the time of last known contact or 30 months, whichever was
earlier. Secondary analyses included examining these same outcomes on all randomized
subjects over the 21-month post-randomization period, the last three months of which
subjects were not receiving randomized treatment, and hazards before and after study drugdiscontinuation were assessed for qualitative differences.
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For bleeding, the primary non-inferiority assessment was performed on randomized subjects
treated with drug-eluting stents who completed at least 17 months of follow-up (the
minimum allowable visit window for the 18 month post-randomization visit) or experienced
a moderate or severe bleeding event. Bleeding event rates are presented as percentages. The
moderate or severe bleeding hazard ratio is also presented as a post hoc descriptive analysis.
To account for missing data, we repeated the treatment comparisons including all
randomized subjects using multiple imputation19 logistic regression modeling with baseline
covariates (50 imputations) for missing data regarding the primary end points. We also
assessed the consistency of the treatment effect on the primary end points for 14 prespecified factors assessed at baseline.

Results
Study Population
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Between Aug 13, 2009 and July 1, 2011, a total of 25,682 subjects from 452 sites in 11
countries were enrolled in the DAPT Study, of whom 22,866 received a drug-eluting stent.
Among these subjects, 5,261 (23.0%) were not eligible for randomization after 12 months of
follow-up, 7,644 (33.4%) were eligible but not randomized (Supplementary Appendix Table
S2), and 9,961 (43.6%) were randomized (Figure 1). Among those who were eligible but not
randomized, the most common reason was withdrawal of consent during the year between
enrollment and randomization (76%).
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Baseline characteristics of randomized subjects treated with drug-eluting stents were similar
between treatment groups (Table 1). Overall, 26% presented with acute myocardial
infarction, and 50.9% had at least one clinical or lesion-related risk factor for stent
thrombosis (Supplementary Appendix Table S1). Rates of discontinuation of study drug
were not different for the continued thienopyridine and placebo groups at 30 months (21.4%
vs. 20.3%, respectively, P=0.18).
Stent Thrombosis and Major Adverse Cardiovascular and Cerebrovascular Events
Over the primary analysis period for all randomized subjects, the continued thienopyridine
group experienced a significantly lower cumulative incidence of stent thrombosis (0.4% vs.
1.4%, hazard ratio 0.29, 95% CI 0.17-0.48, P<0.001) and major adverse cardiovascular and
cerebrovascular events (4.3% vs. 5.9%, hazard ratio 0.71, 95% CI 0.59-0.85, P<0.001),

N Engl J Med. Author manuscript; available in PMC 2015 June 26.
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compared with the placebo group (Table 2a and Figures 2 and 3). Continued thienopyridine
was associated with a lower cumulative incidence of myocardial infarction than placebo
(2.1% vs. 4.1%, hazard ratio 0.47, P<0.001, Supplementary Appendix Figure S1), of which
non-stent thrombosis-related myocardial infarction comprised 55% of the treatment benefit
(1.8% vs. 2.9% hazard ratio 0.59, P<0.001). Rates of cardiac mortality (0.9% vs. 1.0%,
P=0.98), vascular mortality (0.1% vs. 0.1%, P=0.98), and stroke (0.8% vs 0.9%, P=0.32)
were similar between groups. Total mortality rates were 2.0% and 1.5%, respectively
(hazard ratio 1.36, 95% CI 1.00-1.85, P=0.052, Supplementary Appendix Figure S2). The
results using multiple imputation were consistent (hazard ratio for stent thrombosis 0.27,
P<0.001; hazard ratio for major adverse cardiovascular and cerebrovascular events 0.77,
P=0.002, Supplementary Appendix Table S3a), as were the findings when the analysis
period included the three months after study drug discontinuation (Supplementary Appendix
Table S4).
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Bleeding
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Rates of moderate or severe bleeding for the primary analysis period were significantly
higher in the continued thienopyridine group (2.53% vs. 1.57%, hazard ratio 1.61, 95% CI
1.21-2.16, P=0.001), and did not meet the pre-specified definition of non-inferiority versus
placebo (P=0.70, Table 2b). There was not a significant difference between randomized
treatments in GUSTO severe bleeding (0.81% vs. 0.56%, P=0.15) or in BARC fatal bleeding
(type 5, 0.15% vs. 0.09%, P=0.38), in the continued thienopyridine vs. placebo groups,
respectively. More details of bleeding results by BARC subtype are shown in
Supplementary Appendix Table S5. The results using multiple imputation were consistent
(risk difference for moderate or severe bleeding 0.98%, P=0.73 for non-inferiority,
Supplementary Appendix Table S3b), as were the findings when the analysis period
included the three months after study drug discontinuation (Supplementary Appendix Table
S6).
Mortality
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Over the primary analysis period of 12 to 30 months, the rates of all-cause mortality in the
continued thienopyridine and placebo groups were 2.0% and 1.5%, respectively (hazard
ratio 1.36, P=0.052). During the secondary analysis period of 12 to 33 months, all-cause
mortality was 2.3% vs. 1.8% (hazard ratio 1.36, P=0.04, Supplementary Appendix Figure S2
and Table S4), the difference accounted for by non-cardiovascular death (1.1% vs. 0.6%,
hazard ratio 1.80, P=0.01). Among these non-cardiovascular deaths, bleeding-related death
(N=11 vs. 3, P=0.057) was mainly related to fatal trauma (N=7 vs. N=2, P=0.07). Cancerrelated death differed between groups (N=31 vs. 14, P=0.02), and was mediated by bleeding
in a few cases (N=3 vs. 0, Supplementary Appendix Table S7).
There were 22 more subjects with a history of cancer at baseline in the thienopyridine group
(Supplementary Appendix Table S8), and blinded review of cancer-related deaths identified
an imbalance in the number of randomized subjects where the cancer had been diagnosed
prior to enrollment (8 vs. 1, Supplementary Appendix Table S9). When these subjects were
excluded in a post hoc sensitivity analysis, differences in mortality were no longer
significant (Supplementary Appendix Table S10).

N Engl J Med. Author manuscript; available in PMC 2015 June 26.
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The effect of continued thienopyridine versus placebo on the primary endpoints and on
myocardial infarction was consistent across most subgroups (Supplementary Appendix
Figure S3). Hazards after thienopyridine discontinuation are presented in the Supplementary
Appendix.

Discussion

Author Manuscript

Among patients receiving drug-eluting coronary stents, continued thienopyridine and aspirin
beyond one year reduced the risk of stent thrombosis and major adverse cardiovascular and
cerebrovascular events compared with aspirin alone. This treatment benefit was driven by
concurrent reductions in stent thrombosis and in myocardial infarction. Longer
thienopyridine administration was also associated with more bleeding, although severe or
fatal bleeding was uncommon and not significantly different between study groups.
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The DAPT Study included a large proportion of subjects with stent thrombosis risk factors,
including many with preceding myocardial infarction. Across almost all subjects and lesion
types, continued thienopyridine was associated with reductions in the risk of both coprimary end points. Different stents20,21 and P2Y12 inhibitors22 have been associated with
varied rates of stent thrombosis and myocardial infarction in previous reports, yet in this
study, thienopyridine use beyond one year reduced the risks of both outcomes across all
stent and drug types. Although results from prior studies vary with regard to risk of
thienopyridine discontinuation after 6 months, 10-13,23,24 the current study detected an
increased risk of myocardial infarction (both stent- and non-stent related) during the first
three months after discontinuation in both treatment groups. Future evaluation of
thienopyridine therapy to suppress risks of cardiovascular events beyond the duration of this
study may be warranted.
An unexpected finding was that all-cause mortality during the treatment period was
numerically higher for the continued thienopyridine group, driven by an increase in noncardiovascular deaths. While the diagnosis of cancer did not differ after randomization,
cancer-related death was more frequent in subjects treated with continued thienopyridine
and may reflect a chance imbalance in subjects with known cancer prior to enrollment.
While one study comparing long-term thienopyridine therapy to placebo in subjects with
lacunar stroke identified an unexpected increase in mortality,25 other large randomized
studies in subjects with coronary artery disease have not identified either increased or
decreased risks of mortality.26-28
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Several limitations of the study should be considered. First, only drug-compliant subjects
who did not have major adverse cardiovascular and cerebrovascular events, stent thrombosis
or moderate or severe bleeding in the first year were randomized, which may have selected
for subjects at lower risk for late adverse events. Second, while we did not quantify the net
impact of ischemic and bleeding events; decision analysis suggests that small absolute
differences in cardiovascular event rates may be sufficient29 to counterbalance bleeding
risks. Third, while four different metal platform durable polymer drug-eluting stents and two
platelet P2Y12 inhibitors were included, whether the treatment benefits observed will be
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generalizable to other stent types30,31 or non-thienopyridine P2Y12 inhibitors32,33 is
unknown. Additionally, since stent and drug type were not randomized, direct comparisons
of different stent or drug types may be confounded, and within-subgroup estimates of
treatment effect may be underpowered.
In conclusion, in patients treated with drug-eluting stents, continuation of thienopyridine
plus aspirin beyond one year reduced the risks of ischemic events compared with aspirin
alone. Reduction in risk of ischemic events was consistent across drug and stent types, and
was evident regardless of risk of stent thrombosis. The clinical benefit of extended
thienopyridine treatment was tempered by an increase in bleeding events.

Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Subject Randomization and Follow-Up

Author Manuscript

Subjects were enrolled within 72 hours of stent placement, followed for 12 months on openlabel thienopyridine plus aspirin, then randomized to 18 months of thienopyridine or placebo
(each in addition to aspirin). Randomized treatment ended at 30 months and subjects
remained on aspirin only and were followed for another 3 months. While the number of
subjects with clinical follow-up available is reported in each arm, the co-primary efficacy
endpoints were analyzed according to the principle of intention to treat, including all
randomized subjects and last available follow-up information.
*Subjects may have >1 event.
**Site terminated participation, randomization target met prior to subject follow-up, or
subject not recognized to be eligible by site
† Subjects moved, were incarcerated, or were prematurely exited from the study.

N Engl J Med. Author manuscript; available in PMC 2015 June 26.

Mauri et al.

Page 12

Author Manuscript
Author Manuscript

Figure 2. Cumulative Incidence of Stent Thrombosis, According to Treatment Group

Author Manuscript

Cumulative incidence curve is shown for the primary effectiveness outcome of stent
thrombosis in the intention-to-treat analysis population. Randomization occurred at 12
months after stenting. The primary analysis period was 12-30 months after percutaneous
coronary intervention, i.e. the 18 months after randomization over which subjects were
treated with study drug. Subjects were followed for an observational period of an additional
three months, off study drug and off open label thienopyridine treatment, to a total of 33
months, i.e. 21 months post randomization. P values were calculated with stratified log-rank
test. The number at risk is defined as the number of subjects without the event of interest
and available for subsequent follow-up. The numbers at risk at the start of final 33 month
visit (i.e. 20 months post randomization) were 4,438 vs. 4,362 for continued thienopyridine
vs. placebo, respectively.
Abbreviations: ARC, Academic Research Consortium; HR, hazard ratio; MACCE, major
adverse cerebral and cardiovascular events.
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Figure 3. Cumulative Incidence of Major Adverse Cardiovascular and Cerebrovascular Events
(MACCE) According to Treatment Group

Author Manuscript

Cumulative incidence curve is shown for the primary effectiveness outcome of MACCE in
the intention-to-treat analysis population. Randomization occurred at 12 months after
stenting. The primary analysis period was 12-30 months after percutaneous coronary
intervention, i.e. the 18 months after randomization over which subjects were treated with
study drug. Subjects were followed for an observational period of an additional three
months, off study drug and off open label thienopyridine treatment, to a total of 33 months,
i.e. 21 months post randomization. P values were calculated with stratified log-rank test.
Error The number at risk is defined as the number of subjects without the event of interest
and available for subsequent follow-up. The numbers at risk at the start of final 33-month
visit (i.e. 20 months post randomization) were 4,336 vs. 4,217 for continued thienopyridine
vs. placebo, respectively.
Abbreviations: ARC, Academic Research Consortium; HR, hazard ratio; MACCE, major
adverse cerebral and cardiovascular events.
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Table 1

Characteristics of Randomized Subjects Treated with Drug-Eluting Stents*

Author Manuscript

Measure

Continued Thienopyridine
N=5020 Subjects

Placebo
N=4941 Subjects

61.8± 10.2

61.6 ± 10.1

Subject Characteristics
Age (years)
Female
Race-Non- White

1242 (24.7%)

1284 (26.0%)

438/4918 (8.9%)

419/4847 (8.6%)

Author Manuscript

Hispanic or Latino

159/4924 (3.2%)

159/4847 (3.3%)

Weight (kg)

91.5± 19.7 (5009)

91.5±19.4 (4931)

BMI (Kg/m2 )

30.5± 5.8 (4973)

30.6±5.8 (4901)

Diabetes mellitus

1556/5006 (31.1%)

1481/4927 (30.1%)

Hypertension

3796/5006 (75.8%)

3649/4934 (74.0%)

Current cigarette smoker or within past year

1222/4965 (24.6%)

1210/4893 (24.7%)

Stroke/TIA

155/5006 (3.1%)

169/4931 (3.4%)

Congestive heart failure

238/5001 (4.8%)

223/4926 (4.5%)

Peripheral arterial disease

284/4937 (5.8%)

284/4857 (5.8%)

Prior PCI

1518/4995 (30.4%)

1529/4928 (31.0%)

Prior CABG

568/5012 (11.3%)

581/4930 (11.8%)

Prior MI

1092/4953 (22.0%)

1026/4870 (21.1%)

Positive stress test**

1487/3916 (38.0%)

1485/3843 (38.6%)

STEMI

534 (10.6%)

511 (10.3%)

NSTEMI

776 (15.5%)

767 (15.5%)

Unstable angina***

838 (16.7%)

825 (16.7%)

Stable angina

1882 (37.5%)

1870 (37.8%)

Other

990 (19.7%)

968 (19.6%)

4502 (89.7%)

4416 (89.4%)

Europe

402 (8.0%)

405 (8.2%)

Australia/New Zealand

116 (2.3%)

120 (2.4%)

Clopidogrel

3275 (65.24%)

3230 (65.37%)

Prasugrel

1745 (34.76%)

1711 (34.63%)

Everolimus-eluting

2345 (46.71%)

2358 (47.72%)

Paclitaxel-eluting

1350 (26.89%)

1316 (26.63%)

Zotarolimus-eluting†

642 (12.79%)

622 (12.59%)

Sirolimus-eluting

577 (11.49%)

541 (10.95%)

>1 DES type

106 (2.11%)

104 (2.10%)

Indication for PCI

Author Manuscript

Region
North America

Treatment Characteristics

DES type at index procedure

Author Manuscript
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Continued Thienopyridine
N=5020 Subjects

Placebo
N=4941 Subjects

Number of treated lesions

1.30±0.55

1.29±0.54

Number of treated vessels

1.11±0.33

1.12±0.34

Number of stents

1.47±0.75

1.45±0.75

<3

2341 (46.63%)

2293 (46.41%)

=3

1593 (31.73%)

1595 (32.28%)

>3

1086 (21.63%)

1053 (21.31%)

27.70±16.77

27.43±17.02

N=6594 Lesions

N=6413 Lesions

6396/6586 (97.12%)

6204/6407 (96.83%)

Measure

Author Manuscript

Minimum stent diameter

Total stent length
Lesion Characteristics
Treated vessel(s)
Native coronary

Author Manuscript

Left main

55/6586 (0.84%)

55/6407 (0.86%)

LAD

2715/6586 (41.22%)

2586/6407 (40.36%)

RCA

2153/6586 (32.69%)

2057/6407 (32.11%)

Circumflex

1473/6586 (22.37%)

1506/6407 (23.51%)

Venous graft

154/6586 (2.34%)

173/6407 (2.70%)

Arterial graft

36/6586 (0.55%)

30/6407 (0.47%)

2754/6335 (43.47%)

2643/6137 (43.07%)

Modified ACC/AHA lesion class B2 or C‡
*

There were no significant differences between the two groups except for hypertension (P=0.03).

Denominators are shown when they differed from the total number in the treatment group.
Abbreviations: ACC, American College of Cardiology; AHA, American Heart Association; BMI, body mass index; CABG, coronary artery bypass
graft; LAD, left anterior descending; MI, myocardial infarction; NSTEMI, non-ST elevation MI; PCI, percutaneous coronary intervention; RCA,
right coronary artery; STEMI, ST-elevation MI; TIA, transient ischemic attack.

Author Manuscript

**

For most variables, 0-3% of patients had missing values; 6% of patients were missing lesion class; 22% of patients were missing positive stress
test due to not being collected in one contributing study.
***

Without reported cardiac enzyme elevation.

†

Endeavor stent.
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Table 2a

Author Manuscript

Stent Thrombosis and Major Adverse Cardiovascular and Cerebrovascular Events
(MACCE)
Subjects were randomized to 18 months of either continued thienopyridine or placebo plus aspirin 12 months
after receiving a drug-eluting stent. Data are presented according to intention-to-treat. The primary analysis
period was 12-30 months after enrollment, and the study co-primary effectiveness end points were stent
thrombosis and MACCE. Hazard ratios are presented as continued thienopyridine vs. placebo.
Continued Thienopyridine
N=5020

Placebo
N=4941

Stratified Hazard Ratio
(95% CI)

Stratified Log-rank P Value

19 (0.4%)

65 (1.4%)

0.29 (0.17, 0.48)

<0.001

ARC definite

15 (0.3%)

58 (1.2%)

0.26 (0.14, 0.45)

<0.001

ARC probable

5 (0.1%)

7 (0.1%)

0.71 (0.22, 2.23)

0.55

211 (4.3%)

285 (5.9%)

0.71(0.59, 0.85)

<0.001

98 (2.0%)

74 (1.5%)

1.36 (1.00, 1.85)

0.052

Cardiac

45 (0.9%)

47 (1.0%)

1.00 (0.66, 1.52)

0.98

Vascular

5 (0.1%)

5 (0.1%)

0.98 (0.28, 3.39)

0.98

Non-cardiovascular

Outcome
Stent thrombosis

MACCE (death, MI, or stroke)

Author Manuscript

Death

48 (1.0%)

22 (0.5%)

2.23 (1.32, 3.78)

0.002

MI

99 (2.1%)

198 (4.1%)

0.47 (0.37, 0.61)

<0.001

Stroke

37 (0.8%)

43 (0.9%)

0.80 (0.51, 1.25)

0.32

Ischemic

24 (0.5%)

34 (0.7%)

0.68 (0.40, 1.17)

0.16

Hemorrhagic

13 (0.3%)

9 (0.2%)

1.20 (0.50, 2.91)

0.68

Type uncertain

0 (0.0%)

1 (0.0%)

0 (--, --)

0.32

Abbreviations: ARC, Academic Research Consortium; ASA, aspirin; MACCE, major adverse cardiovascular and cerebrovascular events; MI,
myocardial infarction; ST, stent thrombosis.
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122 (2.59%)
7 (0.15%)

BARC Type 3

BARC Type 5

4 (0.09%)

68 (1.46%)

72 (1.55%)

137 (2.95%)

0.06% (-0.08%, 0.20%)

1.13% (0.56%, 1.70%)

1.53% (0.92%, 2.14%)

2.64% (1.82%, 3.45%)

0.69% (0.22%, 1.16%)

0.25% (-0.09%, 0.58%)

0.96% (0.38%, 1.53%)

Risk Difference
(95% CI)

0.38

<0.001

<0.001

<0.001

0.004

0.15

0.001

Two-sided P Value for Difference
0.70

One-sided P Value for Non-Inferiority

Abbreviations: BARC, Bleeding Academic Research Consortium; GUSTO, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries.

145 (3.08%)

BARC Type 2

48 (1.03%)

81 (1.72%)
263 (5.58%)

GUSTO Moderate

BARC Types 2, 3, or 5

26 (0.56%)

38 (0.81%)

GUSTO Severe

73 (1.57%)

119 (2.53%)

GUSTO Severe/Moderate

Placebo
N=4650

Continued Thienopyridine
N=4713

Bleeding Complications

The primary safety end point was GUSTO Moderate or Severe bleeding. The one-sided test of non-inferiority (based on a delta of 0.8%) was calculated
according to the Farrington-Manning approach. Only evaluable subjects were included in this analysis, e.g. subjects whose last contact date was ≥ 510
days post randomization or who experienced any adjudicated bleeding outcome at or before 540 days. The secondary analysis of BARC results by
subtype are shown in Supplementary Appendix Table S5.
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Bleeding Outcomes at 12-30 Months
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